Physician profile
Patrick J Rose
NPI 1811208341
$18,681.91
in general payments reported to CMS, 2019-2025
58 companies · $2,242 in 2025
The $2,242 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,084 · 2020: $2,689 · 2021: $3,598 · 2022: $2,983 · 2023: $3,017 · 2024: $2,070 · 2025: $2,242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,328.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,308.69 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,421.02 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,388.24 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $1,330.40 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $922.83 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $887.87 | 2019-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $858.35 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $714.96 | 2019-2025 | Repatha, Otezla, Otezla |
| Merck Sharp & Dohme LLC | $714.38 | 2019-2023 | Belsomra, Steglatro, Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $686.96 | 2019-2025 | Jardiance, Synjardy, Combivent Respimat |
| Allergan, INC. | $674.74 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $550.48 | 2019-2023 | Xarelto |
| Kowa Pharmaceuticals America, INC. | $396.28 | 2022-2023 | Seglentis, Livalo |
| Gilead Sciences, INC. | $379.75 | 2020-2025 | |
| Otsuka America Pharmaceutical, INC. | $350.10 | 2020-2025 | Rexulti |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Rose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.